| GSK5959 |
化合物GSK 5959 |
901245-65-6 |
| MHY1485 |
MHY1485 |
326914-06-1 |
| AHAS inhibitor |
BTB06584 |
219793-45-0 |
| UNC0379 |
UNC0379 |
1620401-82-2 |
| PF-543 |
PF-543 |
1706522-79-3 |
| GPR84 antagonist 8 |
GPR84 ANTAGONIST 8 |
1445846-30-9 |
| N,N'-(Dithiodi-2,1-ethanediyl)bis[2,5-dichloro-benzenesulfonaMide |
KC7F2 |
927822-86-4 |
| LJI308 |
LJI308 |
1627709-94-7 |
| AZD-1208 |
AZD1208 |
1204144-28-4 |
| KO-947 |
KO-947 |
1695533-89-1 |
| 1,6-Naphthyridine-3-carboxylic acid, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)- |
非奈利酮杂质01 |
2640506-74-5 |
| 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl- |
非奈利酮杂质04 |
2084136-51-4 |
| 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-1,4,5,6-tetrahydro-2,8-dimethyl-5-oxo- |
非奈利酮杂质05 |
2087452-81-9 |
| 1,6-Naphthyridine-3-carboxylic acid, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, 2-cyanoethyl ester, (4S)- |
2-CYANOETHYL (S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4- DIHYDRO-1,6-NAPHTHYRIDINE-3- |
2640574-73-6 |
| 1627710-50-2 |
2,6-二氟-4-[4-[4-(4-甲基-1-哌嗪基)苯基]-3-吡啶基]苯酚 |
1627710-50-2 |
| Benzenecarboximidic acid, 4-[3-(aminocarbonyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridin-4-yl]-3-methoxy-, ethyl ester |
非奈利酮杂质D |
2640280-83-5 |
| Benzenecarboximidic acid, 4-[3-(aminocarbonyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridin-4-yl]-3-methoxy-, methyl ester |
非奈利酮杂质A |
2640280-82-4 |
| 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-1,4-dihydro-5-methoxy-2,8-dimethyl- |
非奈利酮杂质11 |
2640280-84-6 |
| Phenylmethyl 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxylate |
非奈利酮中间体 |
2820463-47-4 |
| 1,6-Naphthyridine-3-carboxylic acid, 4-(4-cyano-2-methoxyphenyl)-1,4,5,6-tetrahydro-2,8-dimethyl-5-oxo-, phenylmethyl ester |
非奈利酮中间体 |
2389020-00-0 |
QQ
微信
